Myriad's BRACAnalysis CDx(R) test successfully identified metastatic breast cancer
Myriad Genetics announced new findings from the OlympiAD study that show its BRACAnalysis CDx® test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza (olaparib), AstraZeneca's PARP inhibitor. February 17, 2017